1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Eyebright Medical Technology (Beijing) Co., Ltd. Class A

Eyebright Medical Technology (Beijing) Co., Ltd. Class A

SSSE:688050
42.48
CNY
+1.04
(+2.51%)
1.35EPS
24.99P/E
7.05BMarket Cap
Oct 28Next Earn
Eyebright Medical Technology (Beijing) Co., Ltd. Class A
SSE:688050
(Shanghai Stock Exchange)

Recent

price

42.48

P/E

ratio

24.99

div

yld

1.06%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.35
0.63
0.97
1.38
1.7
2.29
3.06
5.04
7.44
7.74
8.81
Revenue per Share
-0.01
-0.03
0.16
0.47
0.6
0.91
1.23
1.61
2.05
1.4
1.46
Basic EPS, GAAP
-0.25
-0.23
-0.31
-0.65
0.03
-0.49
-0.11
-0.84
0.1
1.28
- -
Free Cash Flow per Basic Share
0.01
0.01
0.01
- -
- -
0.16
0.23
0.33
0.37
0.47
0.45
Dividend per Share
1.32
1.4
3.88
4.35
8.02
8.84
9.83
11.24
12.71
14.42
14.92
Book Value per Share
0.97
1
3.48
3.64
7.43
8.06
8.97
9.2
10.35
11.81
9.35
Tangible Book Value per Share
126
119
131
141
161
189
190
189
189
192
193
Basic Weighted Avg Shares
44
75
127
195
273
433
579
951
1,410
1,483
1,701
Sales/Revenue/Turnover
-18.11
-0.08
17.53
33.02
37.46
38.51
42.61
34.31
33.15
27.18
25.67
Operating Margin (%)
6
8
14
22
27
32
43
77
133
169
- -
Depreciation Expense
-1
-4
20
67
97
171
233
304
388
268
281
Net Income, GAAP
- -
- -
23.98
5.6
13.44
10.66
13.95
12.7
10.21
16.83
18.08
Effective Tax Rate (%)
-3.21
-5.3
16
34.16
35.36
39.56
40.15
31.96
27.55
18.09
16.55
Profit Margin (%)
62
58
338
311
1,069
979
914
645
882
1,246
1,292
Working Capital
16
28
- -
- -
3
155
163
272
494
371
916
LT Debt
188
198
554
648
1,548
1,740
1,920
2,356
2,634
2,970
3,147
Total Equity
- -
- -
5.08
10.89
8.76
9.58
11.18
11.86
13.17
7.19
6.81
Return on Invested Capital (%)
- -
- -
5.22
11.2
8.82
10.19
12.06
13.69
13.7
9.31
8.5
Return on Capital (%)
- -
-2.06
5.42
11.41
9.04
10.74
13.17
15.24
17.11
10.32
10.55
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
209
348
290
LT Borrowings
347
865
884
LT Finance Leases
24
20
33
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
193
193
193
Market Capitalization
11,732
10,030
7,051

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,670
1,941
1,870
Cash, Cash Equivalents & STI
796
729
685
Accounts Receivable, Net
470
687
639
Inventories
313
399
420
Total Current Liabilities
424
624
578
Payables & Accruals
- -
- -
- -
ST Debt
209
348
290
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.01%
12.75%
Free Cash Flow
- -
-75.12%
1,246.45%
Net Income, GAAP
- -
28.14%
-30.96%
Sales/Revenue/Turnover
- -
41.99%
5.15%
Total Cash Common Dividend
- -
47,070.93%
26.79%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
310
375
390
335
1,410
2025
357
430
- -
338
1,483
2026
398
535
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.54
0.56
0.58
0.37
2.05
2025
0.49
0.63
- -
-0.11
1.4
2026
0.46
0.48
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.29
0.03
0.03
0.37
2025
0.03
0.02
- -
0.03
0.47
2026
0.03
0.37
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS) develops, manufactures and markets ophthalmic medical devices with a focus on surgical treatment, myopia management and consumer vision care; core products include intraocular lenses such as the Prosert series (hydrophobic acrylic monofocal, multifocal EDOF and toric models), Loong Crystal phakic refractive IOL and preloaded high-order aspheric IOLs, orthokeratology lenses (corneal orthopaedics including night-wear types), soft and hard contact lenses, capsular tension rings, intraocular lens implantation systems, ophthalmic viscoelastic agents, microsurgical instruments, ophthalmic scalpels and tear test papers. The company, founded in 2010 and headquartered at No. 9 Xingchang Road, Changping Science Park, Changping District, Beijing, China, primarily serves domestic markets in China with expansion into overseas regions; it operates as a National High-tech Enterprise and state-level technologically advanced Little Giant enterprise listed on the Shanghai Stock Exchange STAR Market. Recent developments include a January 2025 strategic partnership with Meituan Health to launch China's first 24-hour smart contact lens store in Beijing integrating humanoid robots and digital marketing, receipt of a Class III medical device certificate for the Loong Crystal PR IOL (for adult myopia -3.25D to -18.00D), a gold medal at the 19th Beijing Invention and Innovation Competition for the Loong Crystal PR Phakic IOL, and a September 2024 memorandum of cooperation with Invest Hong Kong to support global expansion highlighted at the ESCRS Congress.